Group 1 - The core point of the news is that Fujian Cosunter Pharmaceutical Co., Ltd. plans to issue A-shares to specific investors in 2025, aiming to raise a total of up to 976.87 million yuan for various projects, including innovative drug research and development [2][5][10] - The issuance plan has been approved by the company's board and shareholders, but it still requires approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [2][3] - The company intends to issue no more than 47,780,100 shares, which will not exceed 30% of the total share capital before the issuance [5][6] Group 2 - The funds raised will be allocated as follows: approximately 598.38 million yuan for innovative drug R&D, about 88.49 million yuan for traditional Chinese medicine industrialization, and 290 million yuan for working capital [5][10] - The pricing for the shares will be based on the average trading price over the 20 trading days prior to the pricing date, with a minimum price set at 80% of that average [4][5] - The issuance will not change the controlling shareholder or the actual controller of the company, and the profits accumulated before the issuance will be shared by both new and existing shareholders [6][10] Group 3 - The company has faced continuous losses, with net profits of -132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan in recent years, primarily due to high R&D costs and the impact of national drug procurement policies [8][10] - The company is undergoing a strategic transformation from generic drugs to innovative drugs, which requires significant investment and carries inherent risks associated with drug development [9][10] - The company has committed to measures to mitigate the dilution of immediate returns for existing shareholders post-issuance, although this does not guarantee future profits [6][7]

2025 年 7 月 5 日 行业研究 MXD6 具备高阻隔及高刚性特点，国产厂商放量在即空间广阔 ——MXD6 特种尼龙行业动态报告 要点 MXD6 商业化始于 20 世纪 80 年代，兼具高阻隔及高刚性特点。聚己二酰间苯 二甲胺（MXD6）是由间苯二甲胺（MXDA）与己二酸缩聚制得的一类结晶型聚 酰胺。20 世纪 80 年代，日本三菱瓦斯化学公司实现了 MXD6 的工业化。得益 于分子结构中引入的芳香环，MXD6 兼具脂肪族尼龙的易加工性与芳香族聚合物 的高强度，具备高气体阻隔性、高刚性、良好的热稳定性和低吸水率等特性。在 工程应用中，MXD6 通常通过直接熔融缩聚法制得，该工艺具备连续化、产品性 能优异等优势，技术门槛也更高。 基于高阻隔性，MXD6 在食品饮料包装领域用量空间可观。MXD6 因其优异的氧 气和二氧化碳阻隔能力，可应用于食品和饮料的包装材料中。通过与 PA6、PET 等材料共混或共挤，MXD6 可制成多种形态的包装结构，有效延长预制菜、碳酸 饮料、茶饮料等产品的货架期，并实现包装的轻量化。根据艾媒咨询统计，2024 年我国预制菜行业市场规模约为 6972 亿元。根据国家统计局等统计，20 ...

目 录 | 一、关于标的公司业务………………………………………………第 | 1—41 页 | | --- | --- | | 二、关于营业收入………………………………………………… 第 | 41—71 页 | 发行股份及支付现金购买资产暨关联交易 申请的审核问询函 之问询问题中有关财务事项的说明（修订稿） 天健函〔2025〕2-103 号 上海证券交易所： 由国投证券股份有限公司转来的《关于株洲千金药业股份有限公司发行股份 及支付现金购买资产暨关联交易申请的审核问询函》 （上证上审（并购重组） 〔2025〕23 号，以下简称审核问询函）奉悉。我们已对审核问询函所提及的株 洲千金药业股份有限公司（以下简称千金药业公司或公司）关于问询问题中有关 财务事项进行了审慎核查，现汇报如下。（除另有标注外，本说明的金额单位均 为万元，部分合计数与各单项数据之和在尾数上存在差异，这些差异是由于四舍 五入原因所致） 一、关于标的公司业务 根据重组报告书和评估报告：（1）千金湘江药业主要从事化学合成原料药 和固体制剂的研发、生产和销售，主要产品包括缬沙坦胶囊、盐酸地芬尼多片、 马来酸依拉普利片等 13 种产品；千金协力药业主要从 ...

兴化股份在互动平台表示，公司子公司兴化化工 甲醇装置设计产能为30万吨/年，2024年度甲醇产量 32.29万吨。因其装置自身产品配套需要，大部分甲醇自用于生产甲胺、DMF、乙醇等产品，2024年度 兴化化工甲醇产品的对外销售约6.23万吨、销售额（不含税）为1.22亿元。 ...

Core Insights - The conference highlighted that fine chemicals are not only the core driving force for high-quality development in the petrochemical industry but also a strategic support for industrial upgrading and the cultivation of new productive forces [1] Industry Structure - Fine chemicals refer to fine chemical products and new chemical materials, contrasting with basic chemicals, as defined in the "Implementation Plan for the Innovation and Development of the Fine Chemical Industry (2024-2027)" [2] - China's annual production capacity for fine chemicals is nearing 200 million tons, with a supply guarantee rate of 90% [2] - The industry has a strong global competitive position, with market shares of 75% in pesticides, 70% in rubber additives, and 60% in food organic acids and feed vitamins [2] - Structural contradictions exist, with self-sufficiency rates exceeding 130% for food additives and traditional pesticides, while rates for products like photoresists and specialty gases are below 20% [2] Technological Innovation - There is a significant gap between the performance of fine chemicals and downstream expectations, with 99% of fine chemicals producible but lacking stability and quality compared to international standards [3] - Continuous R&D innovation is essential for industry transformation, as exemplified by Shin-Etsu Chemical's evolution from a fertilizer plant to a leading global player in PVC and semiconductor silicon materials [3] - Market-driven technological advancements are crucial, with adhesives evolving from auxiliary materials to functional solutions in various industries [3] Innovation Trends - High-performance fibers, such as PBO fibers, are emerging as key materials, with a single 1mm diameter PBO fiber capable of lifting 450 kg [4] - Silicon carbide fibers are gaining attention for their high-temperature resistance and applications in various industrial sectors [4] - New high-performance materials, including ethylene-acrylic copolymers and carbon nanotubes, are showing promise in multiple applications due to their superior properties [5] - Silicon-based new materials are expected to disrupt the coatings and adhesives industries, with modified silicone resins capable of withstanding extreme temperatures [5]

郑宝山提醒："精细化工的短板就是我们从石化大国向石化强国跨越的绊脚石。" 科技创新驱动产业突围 "目前精细化学品可展现的性能与下游期望值相差巨大。99%的精细化学品我们能做，但产品稳定性与 品质与国际先进水平相比仍有差距。"资深化工行业专家杨向宏说道。 在近日举行的2025全国石油和化工行业科技创新大会开幕式上，工信部原材料司二级巡视员韩敬友指 出："精细化工不仅是石化行业高质量发展的核心动力，更是产业升级与新质生产力培育的战略支 点。"这一论断在大会同期举办的2025精细化工创新发展论坛引发共鸣，与会专家一致认为，精细化是 化工品最大的增长点，破解精细化工行业结构性矛盾、突破科技创新瓶颈，已成为实现石化强国梦的突 破口。 行业结构性矛盾突出 什么是精细化工?石油和化学工业规划院副院长、教授级高级工程师郑宝山指出，按照工信部等九部门 联合发布的《精细化工产业创新发展实施方案(2024—2027年)》中的相关论述，精细化工通常指精细化 学品和化工新材料，是与基础化工相对而言的。 当前，我国精细化学品的年产能已经接近2亿吨，大宗产品供应有余，总体保障率达到90%。相对应 地，精细化工的创新能力和企业创新投入显著提 ...

Group 1 - The company, Fujian Cosunter Pharmaceutical Co., Ltd., plans to issue A-shares to specific investors, with the proposal approved by the board and shareholders [2][3] - The issuance will target no more than 35 specific investors, including qualified institutional investors and individuals, with all subscriptions to be made in cash [3][4] - The pricing for the shares will be based on the average trading price over the 20 trading days prior to the pricing date, set at no less than 80% of that average [4] Group 2 - The total number of shares to be issued will not exceed 47,780,100, representing no more than 30% of the company's total share capital prior to the issuance [5] - The company aims to raise up to 976.87 million yuan, with funds allocated primarily for innovative drug research and development, traditional Chinese medicine industrialization, and working capital [5] - The company will initially use self-raised funds for projects until the raised funds are available, and if the actual net amount raised is less than planned, adjustments will be made based on project priorities [5] Group 3 - After the issuance, the shares subscribed by investors will be subject to a six-month lock-up period [6] - The issuance will not change the controlling shareholder or the actual controller of the company, nor will it affect the distribution of shares in a way that violates listing conditions [6] - The company has committed to measures to compensate for any dilution of immediate returns resulting from the issuance [6] Group 4 - The company has experienced continuous losses, with net profits of -132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan in recent periods, primarily due to increased R&D investments and price declines from centralized procurement policies [10][11] - The company is focusing on innovative drug development, which typically involves high costs and long timelines, and faces risks related to market acceptance and competition [9][10] - The company has established itself as a well-known player in the antiviral drug market, particularly in hepatitis B treatment, with a product portfolio that includes generics and innovative drugs [14]

证券代码：002109 证券简称：兴化股份 陕西兴化化学股份有限公司投资者关系活动记录表 编号：2025002 | | □特定对象调研 | □分析师会议 | | --- | --- | --- | | 投资者关系 活动类别 | □媒体采访 | ☑业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | □电话会议 | | | □其他： （请文字说明其他活动内容） | | | 参与单位名 称及人员姓 | 投资者网上提问 | | | 名 | | | | 时间 | 2025 年 5 月 20 日(周二)15:00～17:00 | | | 地点 | 公司通过全景网"投资者关系互动平台"（https:// ir.p5w.net）采用网络远程的方式召开业绩说明会 | | | | 总经理薛宏伟 | | | 公司接待人 员姓名 | 董事会秘书贾三宝 | | | | 总会计师胡明松 | | | | 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了 回复： | | 投资者关系 活动主要内 容介绍 1、2024 年经营活动现金流净额同比下降 70%，而 投资活动现金 ...

点击注册小程序 查看完整报告 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 低空经济是战略性新兴产业，人形机器人产业化进程有望加速 近年来相关政策密集出台助力低空经济发展，未来我国低空经济的市场规模十分可观。根据中国民航局预 测，25年我国低空经济市场规模将达1.5万亿元，35年有望达3.5万亿元。人形机器人是一个崭新且空间庞 大的蓝海市场，高工机器人产业研究所（GGI）预计24年全球人形机器人市场规模约10.17亿美元，到30年 市场规模将达到150亿美元，24-30年的CAGR将超过56%，全球人形机器人销量将从1.19万台增长至60.57 万台。 海外厂商方面，日本三菱瓦斯化学目前拥有1.9万吨/年MXD6产能，索尔维拥有8000吨/年MXD6产能。国 内厂商方面，中化国际布局有高性能工程塑料MXD6聚合及 ...

海利尔药业集团股份有限公司 证券代码：603639 证券简称：海利尔 公告编号：2025-016 2024 年年度主要经营数据公告 | 主要产品 | 2024 年度 | | 2023 年度 | | 变动比 | | --- | --- | --- | --- | --- | --- | | | 平均进价（万元/吨） | | 平均进价（万元/吨） | | 率（%） | | 丙烯腈 | | 0.82 | | 0.80 | 2.13 | | 二甲基甲酰胺(DMF) | | 0.39 | | 0.46 | -14.52 | | 甲苯 | 0.62 | 0.65 | -4.54 | | --- | --- | --- | --- | | 一甲胺精品 | 0.40 | 0.53 | -25.84 | | 液氯 | 0.028 | 0.026 | 7.95 | 四、其他对公司生产经营具有重大影响的事项 以上生产经营数据，来自公司内部统计，未经审计，仅为投资者及时了解公 司生产经营概况之用，未对公司未来经营情况作出任何明示或默示的预测或保证。 公司董事会提醒投资者审慎使用上述数据。 本公司董事会及全体董事保证本公告内容不存在任 ...